Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $ANNX
Date | Price Target | Rating | Analyst |
---|---|---|---|
3/1/2024 | $11.00 | Neutral → Overweight | JP Morgan |
12/21/2023 | $4.00 → $6.00 | Neutral → Buy | BofA Securities |
10/30/2023 | $11.00 | Overweight | Wells Fargo |
5/26/2023 | $8.00 → $3.00 | Buy → Neutral | BofA Securities |
5/25/2023 | $19.00 → $9.00 | Overweight → Neutral | JP Morgan |
9/16/2022 | $12.00 | Buy | Jefferies |
9/9/2022 | $15.00 | Buy | BTIG Research |
11/30/2021 | $40.00 | Buy | HC Wainwright & Co. |
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to six new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on February 10, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4). In the aggregate, the new non-executive employees received options to purchase 542,000 shares of Annexon common stock. The options carry a ten-year term and a
Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting
BRISBANE, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced presentations on ANX007 in geographic atrophy (GA) at the Macula Society 48th Annual Meeting being held February 12-15 in Charlotte Harbor, Florida. ANX007 is a first-in-kind, non-pegylated antigen-binding fragment (Fab) designed to block C1q locally in the eye with an intravitreal formulation. ANX007 is the only investigational therapy in GA to show significant vision preservation on
Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year
ANX005 First Potential Targeted Therapy for Guillain-Barré Syndrome Advancing Towards 1H 2025 BLA Submission ANX007 First Potential Neuroprotective Therapy for Geographic Atrophy Expected to Complete Enrollment of Phase 3 ARCHER II Trial in 2H 2025 ANX1502 First Oral C1s Inhibitor On Track for Clinical Proof of Concept Data in 1Q 2025 Cash Runway into 2H 2026 to Achieve Key Milestones BRISBANE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced
Annexon upgraded by JP Morgan with a new price target
JP Morgan upgraded Annexon from Neutral to Overweight and set a new price target of $11.00
Annexon upgraded by BofA Securities with a new price target
BofA Securities upgraded Annexon from Neutral to Buy and set a new price target of $6.00 from $4.00 previously
Wells Fargo initiated coverage on Annexon with a new price target
Wells Fargo initiated coverage of Annexon with a rating of Overweight and set a new price target of $11.00
Director Carson William H. bought $17,056 worth of shares (3,200 units at $5.33), increasing direct ownership by 14% to 25,600 units (SEC Form 4)
4 - Annexon, Inc. (0001528115) (Issuer)
Director Carson William H. bought $19,104 worth of shares (3,200 units at $5.97), increasing direct ownership by 17% to 22,400 units (SEC Form 4)
4 - Annexon, Inc. (0001528115) (Issuer)
Director Carson William H. bought $17,536 worth of shares (3,200 units at $5.48), increasing direct ownership by 20% to 19,200 units (SEC Form 4)
4 - Annexon, Inc. (0001528115) (Issuer)
EVP & CHIEF INNOVATION OFFICER Yednock Ted sold $5,331 worth of shares (1,783 units at $2.99), decreasing direct ownership by 2% to 69,582 units (SEC Form 4)
4 - Annexon, Inc. (0001528115) (Issuer)
EVP & CHIEF FINANCIAL OFFICER Lew Jennifer sold $5,322 worth of shares (1,786 units at $2.98), decreasing direct ownership by 2% to 84,682 units (SEC Form 4)
4 - Annexon, Inc. (0001528115) (Issuer)
EVP & CHIEF BUSINESS OFFICER Overdorf Michael sold $4,261 worth of shares (1,425 units at $2.99), decreasing direct ownership by 2% to 93,197 units (SEC Form 4)
4 - Annexon, Inc. (0001528115) (Issuer)
SEC Form 144 filed by Annexon Inc.
144 - Annexon, Inc. (0001528115) (Subject)
Amendment: SEC Form SCHEDULE 13G/A filed by Annexon Inc.
SCHEDULE 13G/A - Annexon, Inc. (0001528115) (Subject)
SEC Form 144 filed by Annexon Inc.
144 - Annexon, Inc. (0001528115) (Subject)
Annexon Expands Board of Directors with Appointment of Commercial Executive William "BJ" Jones
BRISBANE, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced the appointment of William "BJ" Jones to its board of directors. Mr. Jones brings 30 years of U.S. and global commercial and launch experience in the biotechnology industry. "We are thrilled to add BJ to our board of directors at this transformative time for Annexon," said Douglas Love, president and chief executive officer of Annexon. "His deep commercial expertise and proven experience
Annexon Expands Senior Leadership in Commercial, Medical Affairs and Health Economics to Advance Global Late-Stage Neuroinflammatory-Targeted Portfolio
BRISBANE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing novel complement therapies for neuroinflammatory diseases of the body, brain, and eye, today announced the strengthening of its senior leadership team with the appointment of Shikhar Agarwal, M.B.A. as senior vice president, head of commercial, Sunil B. Mehta, Pharm.D as senior vice president of medical affairs and Myoung Kim, PHD, M.A., M.B.A. as vice president of health economics and outcomes research. "We are excited to welcome Shikhar, Sunil and Myoung to the Annexon family as we prepare for commercial development of our flagship programs in Guillain-Barré Syndrome (
Turnstone Biologics Appoints William Waddill to its Board of Directors
SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company's Board of Directors. The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors. These changes became effective as of April 15, 2024. "I am pleased to welcome Will to our Board of Directors at this exciting time for Turnstone," said Sammy Farah, M.B.A.,
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)
Real-World Evidence Study Strengthens the Body of Evidence Supporting ANX005 for Treatment of GBS ANX005 Phase 3 Population Was Matched 1:1 on Prespecified Criteria with Patients in International GBS Outcomes Study (IGOS) Matched Cohort Study Showed Early and Greater Benefits of ANX005 over IVIg or PE in Muscle Strength and Functional Outcomes Across Multiple Measurements Conference Call and Webcast Today at 8:30 a.m. ET BRISBANE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
Single Infusion of ANX005 30 mg/kg Met Primary Endpoint, Delivering a Highly Statistically Significant and Clinically Meaningful 2.4-fold Improvement in GBS-DS vs. Placebo at Week 8, p=0.0058 ANX005 Demonstrated Early and Sustained Improvements in Key Secondary Endpoints Including Muscle Strength, Nerve Damage and Ventilation ANX005 Displayed Rapid Target Engagement and was Generally Well-Tolerated Across Doses Real-World Evidence (RWE) Comparability Data Expected in First Half 2025 Conference call and webcast today at 8:30 a.m. ET BRISBANE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage platform of novel ther
Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data
BRISBANE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it will host a conference call and webcast on Tuesday, June 4, 2024, at 8:30 a.m. ET to discuss GBS phase 3 data. Conference Call and Webcast InformationThe live webcast and replay may be accessed by visiting Annexon's website here. The dial-in number is 1-877-407-0784 (U.S./Canada) or 1-201-689-8560 (international). The conference ID for all callers is 13747058. The Call me™ link may be accessed here. Participants can use guest
Amendment: SEC Form SC 13G/A filed by Annexon Inc.
SC 13G/A - Annexon, Inc. (0001528115) (Subject)
Amendment: SEC Form SC 13G/A filed by Annexon Inc.
SC 13G/A - Annexon, Inc. (0001528115) (Subject)
Amendment: SEC Form SC 13G/A filed by Annexon Inc.
SC 13G/A - Annexon, Inc. (0001528115) (Subject)